EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Population pharmacokinetic modeling of vedolizumab for graft‐versus‐host disease prophylaxis in adults with allogeneic hematopoietic stem cell transplant

Timothy Waterhouse iD, Kyle Baron iD, Westley Eure iD, Chunlin Chen, Nathanael L Dirks iD, Johan Jansson, Mona Akbari, Shailly Mehrotra

Pharmacology Research & Perspectives · 2024

DOI: 10.1002/prp2.1257 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmacology Research & Perspectives, 2024. Verfasst von Timothy Waterhouse und 7 weiteren Autor:innen. Beteiligte Einrichtung: Metrum Research Group, Tariffville, Connecticut, USA. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Graft vs Host Disease, Hematopoietic Stem Cell Transplantation, Models, Biological. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Takeda Pharmaceuticals International.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We aimed to characterize the population pharmacokinetics (PK) of vedolizumab for acute graft‐versus‐host disease prophylaxis in adults undergoing allogeneic hematopoietic stem cell transplantation (allo‐HSCT) and assess potential clinically relevant covariates. Dosing, patient characteristics, and PK from a phase 1b, open‐label, dose‐finding study of vedolizumab 75 mg initial dose escalated to 300 mg and a phase 3 study of vedolizumab 300 mg in patients receiving allo‐HSCT were analyzed using a two‐compartment population PK model with linear elimination. Covariates included age, race, weight, sex, albumin, lymphocyte count, GvHD type, and concomitant medications. Weight, albumin, and lymphocyte count were time‐varying covariates. Model selection was driven by goodness‐of‐fit criteria, precision of parameter estimates, and visual predictive checks. In 193 patients undergoing allo‐HSCT, vedolizumab PK were well described by a two‐compartment, linear PK model. Using reference covariate values, final parameter estimates (95% confidence intervals [CI]) were: clearance, 0.148 (0.136, 0.162) L/day; central volume of distribution, 3.12 (3.03, 3.21) L; intercompartmental clearance, 0.500 (0.408, 0.612) L/day; and peripheral volume of distribution, 3.95 (3.52, 4.44) L. Weight and albumin were the most important predictors of vedolizumab PK, with clearance decreasing by ≈20% for low body weight/high albumin and increasing by ≈30% for high body weight/low albumin. There was an inverse relationship between vedolizumab clearance and age, but no detectable effect for lymphocyte count or GvHD type. Post hoc analyses did not detect any relationship between vedolizumab PK and concomitant medications. In summary, the covariates studied did not have a clinically meaningful effect on the PK of vedolizumab.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedGraft vs Host DiseaseHematopoietic Stem Cell TransplantationModels, BiologicalTransplantation, HomologousAdolescentAdultAgedFemaleHumansMaleMiddle AgedYoung AdultDose-Response Relationship, DrugGastrointestinal AgentsClinical Trials, Phase I as TopicClinical Trials, Phase III as TopicRandomized Controlled Trials as TopicMulticenter Studies as Topic

Stichwörter der Autor:innen

allogeneic hematopoietic stem cell transplantationgraft‐versus‐host disease (GvHD)population pharmacokineticsprophylaxisvedolizumab

Substanzen

Antibodies, Monoclonal, HumanizedGastrointestinal Agentsvedolizumab

Autor:innen und Institutionen

  • Metrum Research Group, Tariffville, Connecticut, USA.
  • Takeda Pharmaceuticals Inc., Cambridge, Massachusetts, USA.

ORCID-Profile: Timothy Waterhouse, Kyle Baron, Westley Eure, Nathanael L Dirks

Förderung

  • Takeda Pharmaceuticals International

Zitieren

APA

Waterhouse, T., Baron, K., Eure, W., Chen, C., Dirks, N. L., Jansson, J., Akbari, M., & Mehrotra, S. (2024). Population pharmacokinetic modeling of vedolizumab for graft‐versus‐host disease prophylaxis in adults with allogeneic hematopoietic stem cell transplant. Pharmacology Research & Perspectives. https://doi.org/10.1002/prp2.1257

Vancouver

Waterhouse T, Baron K, Eure W, Chen C, Dirks NL, Jansson J, et al. Population pharmacokinetic modeling of vedolizumab for graft‐versus‐host disease prophylaxis in adults with allogeneic hematopoietic stem cell transplant. Pharmacology Research & Perspectives. 2024. doi:10.1002/prp2.1257

BibTeX
@article{Waterhouse2024,
  author = {Waterhouse, Timothy and Baron, Kyle and Eure, Westley and Chen, Chunlin and Dirks, Nathanael L and Jansson, Johan and Akbari, Mona and Mehrotra, Shailly},
  title = {Population pharmacokinetic modeling of vedolizumab for graft‐versus‐host disease prophylaxis in adults with allogeneic hematopoietic stem cell transplant},
  journal = {Pharmacology Research & Perspectives},
  year = {2024},
  doi = {10.1002/prp2.1257}
}
Kostenlos starten →